X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/09/2860240/0/en/IMM-1-104-is-Synergistic-with-Chemotherapy-in-Pancreatic-Cancer-Models.html
https://www.globenewswire.com/news-release/2024/04/03/2857344/0/en/Immuneering-to-Participate-in-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/03/27/2853079/0/en/Immuneering-Announces-First-Patient-Dosed-in-its-Phase-1-2a-Trial-of-IMM-6-415-to-Treat-Advanced-Solid-Tumors-with-RAF-or-RAS-Mutations.html
https://www.globenewswire.com//news-release/2024/03/14/2846143/0/en/Immuneering-Announces-Positive-Topline-Results-from-Phase-1-Portion-of-its-Phase-1-2a-Clinical-Trial-of-IMM-1-104-in-RAS-Mutant-Solid-Tumors.html
https://www.globenewswire.com//news-release/2024/03/12/2844480/0/en/Immuneering-Appoints-Thomas-J-Schall-Ph-D-to-its-Board-of-Directors.html
https://www.globenewswire.com//news-release/2024/03/11/2843713/0/en/Immuneering-Doses-First-Patient-in-Phase-2a-Clinical-Trial-of-IMM-1-104-in-RAS-mutant-Solid-Tumors.html
https://www.globenewswire.com//news-release/2024/03/05/2840973/0/en/Immuneering-to-Present-Preclinical-Data-on-Universal-RAS-Program-IMM-1-104-at-American-Association-for-Cancer-Research-Annual-Meeting-2024.html
https://www.globenewswire.com//news-release/2024/03/04/2839526/0/en/Immuneering-to-Participate-in-the-Cowen-44th-Annual-Health-Care-Conference.html
https://www.globenewswire.com//news-release/2024/02/20/2831754/0/en/Immuneering-Receives-FDA-Fast-Track-Designation-for-IMM-1-104-in-Pancreatic-Cancer.html
https://www.globenewswire.com//news-release/2024/02/01/2821914/0/en/Immuneering-Announces-Participation-in-February-Investor-Conferences.html
Market Place
Share 
